Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer; A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.

Bibliographic Details
Title: Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer; A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Authors: Jin-Young Jang, Youngmin Han, Hongeun Lee, Sun-Whe Kim, Wooil Kwon, Kyung-Hun Lee, Do-Youn Oh, Eui Kyu Chie, Seong Ho Choi
Source: Annals of Surgery; Aug2018, Vol. 268 Issue 2, p215-222, 8p
Database: Complementary Index
More Details
ISSN:00034932
DOI:10.1097/SLA.0000000000002705
Published in:Annals of Surgery
Language:English